Thermo Electron, the world leader in analytical instruments launches in Europe the first turn-key ADME/Tox (Absorption, Distribution, Metabolism, Excretion and Toxicology) solution on the market at SBS, Geneva. The LeadStream ADME/Tox SolutionTM, first introduced at Lab Automation 2005, addresses today’s drug discovery challenges by dramatically increasing the availability of early ADME/Tox data and accelerating early-stage drug compound assessment.
In vitro ADME/Tox plays a crucial role in the early assessment of potential drug candidates. Prior to LeadStream, this process was not as streamlined and automated as other phases of drug discovery, such as high-throughput-screening. As a result, pharmaceutical companies were limited in the early identification of the most promising candidates.
“We’ve spent the past few years working to understand the complexities of ADME testing within the drug discovery process, and we’re confident that our integrated yet modular approach will dramatically reduce the time it takes to bring sought-after drugs to market,” said Ian Jardine, Vice President of Global Research and Development at Thermo. “In addition to our comprehensive hardware and software strategy, we have set up our own application laboratory to conduct assays which are widely utilized in the pharmaceutical industry. This effort has provided us with first-hand knowledge of how the LeadStream solution will work in the pharmaceutical researcher’s laboratory.”
“Thermo is uniquely positioned to offer an ADME/Tox solution because of our ability to bring together a multitude of Thermo hardware and software solutions to create a single, integrated, more comprehensive and sophisticated platform for our customers,” said Marijn E. Dekkers, President and CEO of Thermo Electron. “With LeadStream, we’re allowing scientists to generate preclinical profiling results in a shorter time-scale, demonstrating our continued dedication to customer-driven innovation.”